摘要目的：阐明剪切波弹性成像（SWE）对新辅助化疗（NAC）后残存乳腺癌的评估价值。方法：连续纳入进行NAC的乳腺癌患者66例，使用SWE评估NAC后病灶的平均和最大硬度。明确残余肿瘤负荷（RCB）量化的病理反应性与NAC后病灶硬度之间的关联，并以病理完全缓解（pCR）作为诊断金标准，明确SWE硬度指标对pCR的诊断效能。结果：平均及最大硬度与pCR密切相关。诊断试验证实最大硬度的总体诊断效能高于平均硬度（AUC=0.96 vs 0.83），且差异有显著统计学意义（P<0.01）。结论：最大硬度评估乳腺癌NAC后残存癌的效能较好，SWE可为个体化乳腺癌治疗方案提供重要参考。
Abstract：Objective: To elucidate the evaluation of shear-wave elastography(SWE) in the residual breast cancer after neoadjuvant chemotherapy(NAC). Methods: 66 breast cancer patients receiving NAC were consecutively included. The means and maximum stiffness after NAC treatment were assessed by SWE. Correlations between the stiffness and pathological response quantized by residual cancer burden(RCB) were determined. Pathological complete response(pCR) was recorded and considered as gold standard. Diagnostic tests of the stiffness value evaluated by SWE were performed. Results: Correlations between the stiffness and pathological response were significantly positive. The maximum stiffness had significantly better overall diagnostic performance than mean stiffness regarding evaluating pCR, and the difference of diagnostic performance between maximum and mean stiffness was significant(P<0.01). Conclusion: The performance of maximum stiffness for evaluating the residual lesion of breast cancer after NAC is favorable, SWE may facilitate the personalizing treatment of breast cancer.
马玉峰，张 昕，张 微，刘洪姝. 剪切波弹性成像对乳腺癌新辅助化疗后残存癌的评估[J]. 中国临床医学影像杂志, 2018, 29(5): 316-319.
MA Yu-feng, ZHANG Xin, ZHANG Wei, LIU Hong-Shu. Shear-wave elastography for the evaluation of residual breast cancer after neoadjuvant chemotherapy. JOURNAL OF CHINA MEDICAL IMAGING, 2018, 29(5): 316-319.
[1]Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: The ctneobc pooled analysis[J]. Lancet, 2014, 384(9938): 164-172.
[2]Parekh T, Dodwell D, Sharma N, et al. Radiological and pathological predictors of response to neoadjuvant chemotherapy in breast cancer: A brief literature review[J]. Pathobiology, 2015, 82(3-4): 124-132.
[3]Youk JH, Gweon HM, Son EJ. Shear-wave elastography in breast ultrasonography: The state of the art [J]. Ultrasonography, 2017, 36(4): 300-309.
[4]Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast cancer 2013[J]. Ann Oncol, 2013, 24(9): 2206-2223.
[5]Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy[J]. J Clin Oncol, 2007, 25(28): 4414-4422.
[6]Velaei K, Samadi N, Barazvan B, et al. Tumor microenvironment-mediated chemoresistance in breast cancer[J]. Breast, 2016, 30: 92-100.
[7]Giussani M, Merlino G, Cappelletti V, et al. Tumor-extracellular matrix interactions: Identification of tools associated with breast cancer progression[J]. Semin Cancer Biol, 2015, 35: 3-10.
[8]Oskarsson T. Extracellular matrix components in breast cancer progression and metastasis[J]. Breast, 2013, 22(Suppl 2): S66-72.
[9]Ma Y, Zhang S, Zang L, et al. Combination of shear wave elastography and ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer[J]. Eur J Cancer, 2016, 69: 86-101.
[10]Wei SC, Fattet L, Tsai JH, et al. Matrix stiffness drives epithelial-mesenchymal transition and tumour metastasis through a twist1-g3bp2 mechanotransduction pathway[J]. Nat Cell Biol, 2015, 17(5): 678-688.
[11]Fischer KR, Durrans A, Lee S, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance[J]. Nature, 2015, 527(7579): 472-476.
[12]Zheng X, Carstens JL, Kim J, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer[J]. Nature, 2015, 527(7579): 525-530.
[13]Ma Y, Zhang S, Li J, et al. Comparison of strain and shear-wave ultrasonic elastography in predicting the pathological response to neoadjuvant chemotherapy in breast cancers[J]. Eur Radiol, 2017, 27(6): 2282-2291.
[14]Zhu Q, DeFusco PA, Ricci A Jr., et al. Breast cancer: Assessing response to neoadjuvant chemotherapy by using us-guided near-infrared tomography[J]. Radiology, 2013, 266(2): 433-442.
2018, Vol. 29 
